Abstract
We have performed whole genome expression profiling of 28 patient prostate tumor samples and 12 normal prostate samples and identified 55 upregulated and 60 downregulated genes significantly changed in prostate tumor samples compared to normal prostate tissues. Among the members of the upregulated gene set was the developmental transcription factor Homeobox C6 (HOXC6). Silencing of HOXC6 expression using small-interfering RNA (siRNA) resulted in decreased proliferation rates for both androgen-dependent LnCaP cells and the LnCaP-derived androgen-independent C4-2 cell line. Flow cytometry and immunoblotting for the caspase-cleaved form of poly-ADP ribose polymerase (PARP) determined that the decrease in cell numbers was due to increased apoptosis. To validate the specificity of the siRNA-induced apoptosis, LnCaP cells were cotransfected with siRNA specific to the HOXC6 3′UTR and a mammalian expression vector containing the HOXC6 open reading frame, but lacking the 3′UTR. Overexpression of HOXC6 rescued the LnCaP cells from HOXC6 siRNA-induced apoptosis, and increased growth of control GFP siRNA-transfected cells. Expression profiling of HOXC6 siRNA transfections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth factor binding protein-3 (IGFBP-3) as potential proapoptotic repression targets of HOXC6. Our data suggest that HOXC6 may be a novel potential therapeutic target for prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abate-Shen C . (2002). Nat. Rev. Cancer, 2, 777–785.
Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA and Milbrandt J . (2002). Mol. Cell. Biol., 22, 1495–1503.
Aberdam D, Negreanu V, Sachs L and Blatt C . (1991). Mol. Cell. Biol., 11, 554–557.
ACS (2003). American Cancer Society.
Bodey B, Bodey Jr B, Groger AM, Siegel SE and Kaiser HE . (2000a). Anticancer Res., 20, 2711–2716.
Bodey B, Bodey Jr B, Siegel SE and Kaiser HE . (2000b). Anticancer Res., 20, 1769–1780.
Bodey B, Bodey Jr B, Siegel SE and Kaiser HE . (2000c). Anticancer Res., 20, 3281–3286.
Bodey B, Bodey Jr B, Siegel SE, Luck JV and Kaiser HE . (2000d). Anticancer Res., 20, 2717–2721.
Bolstad BM, Irizarry RA, Astrand M and Speed TP . (2003). Bioinformatics, 19, 185–193.
Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP and Gelmann EP . (2000). Cancer Res., 60, 6111–6115.
Braasch DA and Corey DR . (2002). Biochemistry, 41, 4503–4510.
Castronovo V, Kusaka M, Chariot A, Gielen J and Sobel M . (1994). Biochem. Pharmacol., 47, 137–143.
Chariot A, Castronovo V, Le P, Gillet C, Sobel ME and Gielen J . (1996). Biochem. J., 319 (Part 1), 91–97.
Chen H, Nandi AK, Li X and Bieberich CJ . (2002). Cancer Res., 62, 338–340.
Cheng WS, Giandomenico V, Pastan I and Essand M . (2003). Endocrinology, 144, 3433–3440.
Cillo C . (1994). Invasion Metast., 14, 38–49.
DeYoung MP, Tress M and Narayanan R . (2003). Proc. Natl. Acad. Sci. USA, 100, 4760–4765.
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM . (2001). Nature, 412, 822–826.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T . (2001). Nature, 411, 494–498.
Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M and Grone HJ . (2002). Am. J. Pathol., 160, 2169–2180.
Essand M, Vasmatzis G, Brinkmann U, Duray P, Lee B and Pastan I . (1999). Proc. Natl. Acad. Sci. USA, 96, 9287–9292.
Fanayan S, Firth SM, Butt AJ and Baxter RC . (2000). J. Biol. Chem., 275, 39146–39151.
Felsher DW . (2003). Nat. Rev. Cancer, 3, 375–380.
Firth SM and Baxter RC . (2002). Endocrinol. Rev., 23, 824–854.
Garcia-Gasca A and Spyropoulos DD . (2000). Dev. Dyn., 219, 261–276.
Grimberg A, Liu B, Bannerman P, El-Deiry WS and Cohen P . (2002). Int. J. Oncol., 21, 327–335.
Hu G, Lee H, Price SM, Shen MM and Abate-Shen C . (2001). Development, 128, 2373–2384.
Jones FS, Holst BD, Minowa O, De Robertis EM and Edelman GM . (1993). Proc. Natl. Acad. Sci. USA, 90, 6557–6561.
Kawabe T, Muslin AJ and Korsmeyer SJ . (1997). Nature, 385, 454–458.
Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, Cunha GR, Cardiff RD, Shen MM and Abate-Shen C . (2002a). Cancer Res., 62, 2999–3004.
Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM and Abate-Shen C . (2002b). Proc. Natl. Acad. Sci. USA, 99, 2884–2889.
Krishnan AV, Peehl DM and Feldman D . (2003). J. Cell. Biochem., 88, 363–371.
Lewis EB . (1978). Nature, 276, 565–570.
Loy CJ, Sim KS and Yong EL . (2003). Proc. Natl. Acad. Sci. USA, 100, 4562–4567.
Luo L, Yang X, Takihara Y, Knoetgen H and Kessel M . (2004). Nature, 427, 749–753.
Magee JA, Abdulkadir SA and Milbrandt J . (2003). Cancer Cell, 3, 273–283.
Maulbecker CC and Gruss P . (1993). Cell Growth Differ., 4, 431–441.
Miller GJ, Miller HL, van Bokhoven A, Lambert JR, Werahera PN, Schirripa O, Lucia MS and Nordeen SK . (2003). Cancer Res., 63, 5879–5888.
Moreno CS, Park S, Nelson K, Ashby D, Hubalek F, Lane WS and Pallas DC . (2000). J. Biol. Chem., 275, 5257–5263.
Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen IM, Feinberg AP, Jenkins NA, Copeland NG and Shaughnessy Jr JD . (1996). Nat. Genet., 12, 154–158.
Rajah R, Valentinis B and Cohen P . (1997). J. Biol. Chem., 272, 12181–12188.
Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP and Nanus DM . (2000). Mol. Cell Endocrinol., 170, 131–142.
Stein S, Fritsch R, Lemaire L and Kessel M . (1996). Mech. Dev., 55, 91–108.
Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M and Nanus DM . (2001). Cancer Res., 61, 3294–3298.
Sumitomo M, Shen R, Goldberg JS, Dai J, Navarro D and Nanus DM . (2000). Cancer Res., 60, 6590–6596.
Thelen P, Burfeind P, Grzmil M, Voigt S, Ringert RH and Hemmerlein B . (2004). Int. J. Oncol., 24, 1085–1092.
Tusher VG, Tibshirani R and Chu G . (2001). Proc. Natl. Acad. Sci. USA, 98, 5116–5121.
Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B and Kley N . (1999). Oncogene, 18, 127–137.
Wei H and Pallas DC . (2003) unpublished data.
Wolfgang CD, Essand M, Lee B and Pastan I . (2001). Cancer Res., 61, 8122–8126.
Wolfgang CD, Essand M, Vincent JJ, Lee B and Pastan I . (2000). Proc. Natl. Acad. Sci. USA, 97, 9437–9442.
Xia X, Cheng A, Akinmade D and Hamburger AW . (2003). Mol. Cell. Biol., 23, 1717–1725.
Yoshinouchi M, Yamada T, Kizaki M, Fen J, Koseki T, Ikeda Y, Nishihara T and Yamato K . (2003). Mol. Ther., 8, 762–768.
Acknowledgements
We thank Dr Alain Chariot for the generous gift of clones of human HOXC6-1 and HOXC6-2, Dr Leland Chung for the generous gift of the LnCaP, C4-2, DU145, and PC3 cell lines, and Drs Jeremy Boss for use of the Bio-Rad I-cycler and Paul Wade for critical reading of the manuscript and helpful discussions. This research was supported in part by NIH Grant K22-CA96560 to CSM and the Department of Pathology & Laboratory Medicine, Emory University School of Medicine. This work is the subject of a US provisional patent application. The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked ‘advertisement’ in accordance with 18 USC section 1734 solely to indicate this fact.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramachandran, S., Liu, P., Young, A. et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 24, 188–198 (2005). https://doi.org/10.1038/sj.onc.1207906
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207906
Keywords
This article is cited by
-
Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics
Journal of Translational Medicine (2023)
-
High expression of HOXC6 predicts a poor prognosis and induces proliferation and inflammation in multiple myeloma cells
Genes & Genomics (2023)
-
TARP as antigen in cancer immunotherapy
Cancer Immunology, Immunotherapy (2021)
-
Overexpression of SOX4 induces up-regulation of miR-126 and miR-195 in LNCaP prostate cancer cell line
Cytotechnology (2020)
-
HOXC6 gene silencing inhibits epithelial-mesenchymal transition and cell viability through the TGF-β/smad signaling pathway in cervical carcinoma cells
Cancer Cell International (2018)